Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. ADR (NQ: IPHA )

3.460 -0.140 (-3.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,978
Open 3.520
Bid (Size) 3.460 (3)
Ask (Size) 3.520 (3)
Prev. Close 3.600
Today's Range 3.446 - 3.550
52wk Range 1.900 - 4.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
From Innate Pharma SA
Via Business Wire

Performance

YTD
+1.76%
+1.76%
1 Month
+10.19%
+10.19%
3 Month
+63.98%
+63.98%
6 Month
+14.95%
+14.95%
1 Year
-11.05%
-11.05%

More News

Read More
US Stocks Open Lower; Nasdaq Slides Over 100 Points
Via Benzinga
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs
Via Benzinga
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket
Via Benzinga
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer
Via Benzinga
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports Third Quarter Financial Results
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Innate Pharma 2023 Financial Calendar
From Innate Pharma SA
Via Business Wire
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.